PCVXVaxcyte, Inc.
$60.39+39% 1Y
$60.39
$40.3252 weeks$71.34
PCVX as reported
- Net income
- −$1.06B
Net income · +94% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$894M
Free cash flow · +88% year on year · trailing twelve months to Q2 2026
- EPS
- −$7.63
EPS · +86% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$1.06B | +94% | Q2 2026 |
| EPS | −$7.63 | +86% | Q2 2026 |
| ROE | −30% | n/a | Q2 2026 |
| ROA | −27% | n/a | Q2 2026 |
| Free cash flow | −$894M | +88% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Vaxcyte, Inc. (PCVX) · Net incomeNet incomeVaxcyte, Inc. (PCVX)
On our screens:Most shorted stocks